中华医学杂志
中華醫學雜誌
중화의학잡지
National Medical Journal of China
2009年
41期
2902-2905
,共4页
徐京杭%于岩岩%斯崇文%陈新月%韩忠厚%陈勇%李雪迎
徐京杭%于巖巖%斯崇文%陳新月%韓忠厚%陳勇%李雪迎
서경항%우암암%사숭문%진신월%한충후%진용%리설영
拉米夫定%肝炎%乙型%慢性%病毒学%动力学
拉米伕定%肝炎%乙型%慢性%病毒學%動力學
랍미부정%간염%을형%만성%병독학%동역학
Lamivudine%Hepatitis B,chronic%Virology%Kinetics
目的 观察拉米夫定治疗乙型肝炎病毒e抗原(HBeAg)阳性慢性乙型肝炎的早期病毒动态变化.方法 多中心的临床试验,选择门诊及住院的HBeAg阳性慢性乙型肝炎患者,口服拉米夫定0.1 g,每日1次,共24周,应用实时聚合酶链反应(polymerase chain reaction,PCR)定量法检测其治疗前,治疗12 h、1 d,2 d,3 d、1周、2周、4周、12周、24周的血清乙型肝炎病毒(HBV)脱氧核糖核酸(DNA),并应用回归分析估计其病毒动力学参数.结果 共入选172例患者,年龄16~65(31±10)岁,男145例(84.3%),拉米夫定用药后12 h即出现明显的HBV DNA载量下降,平均下降0.45(范围:-1.85~3.86)lg(拷贝/m1),4例患者HBV DNA下降≥2 lg(拷贝/m1);2 d时进一步下降,与基线比较平均下降量1.20(范围:-1.21~4.41)lg(拷贝/ml);1周时继续下降,与基线比较,平均下降量2.01(范围:-0.17~5.79)lg(拷贝/ml).此后一直到24周,HBV DNA载量不断下降.24周时,平均下降量4.10(范围:-0.06~6.68)lg(拷贝/ml).游离病毒半衰期为2.57 d,受感染细胞的半衰期为63.0 d.结论 拉米夫定治疗HBeAg阳性慢性乙型肝炎能快速降低HBV病毒载量.
目的 觀察拉米伕定治療乙型肝炎病毒e抗原(HBeAg)暘性慢性乙型肝炎的早期病毒動態變化.方法 多中心的臨床試驗,選擇門診及住院的HBeAg暘性慢性乙型肝炎患者,口服拉米伕定0.1 g,每日1次,共24週,應用實時聚閤酶鏈反應(polymerase chain reaction,PCR)定量法檢測其治療前,治療12 h、1 d,2 d,3 d、1週、2週、4週、12週、24週的血清乙型肝炎病毒(HBV)脫氧覈糖覈痠(DNA),併應用迴歸分析估計其病毒動力學參數.結果 共入選172例患者,年齡16~65(31±10)歲,男145例(84.3%),拉米伕定用藥後12 h即齣現明顯的HBV DNA載量下降,平均下降0.45(範圍:-1.85~3.86)lg(拷貝/m1),4例患者HBV DNA下降≥2 lg(拷貝/m1);2 d時進一步下降,與基線比較平均下降量1.20(範圍:-1.21~4.41)lg(拷貝/ml);1週時繼續下降,與基線比較,平均下降量2.01(範圍:-0.17~5.79)lg(拷貝/ml).此後一直到24週,HBV DNA載量不斷下降.24週時,平均下降量4.10(範圍:-0.06~6.68)lg(拷貝/ml).遊離病毒半衰期為2.57 d,受感染細胞的半衰期為63.0 d.結論 拉米伕定治療HBeAg暘性慢性乙型肝炎能快速降低HBV病毒載量.
목적 관찰랍미부정치료을형간염병독e항원(HBeAg)양성만성을형간염적조기병독동태변화.방법 다중심적림상시험,선택문진급주원적HBeAg양성만성을형간염환자,구복랍미부정0.1 g,매일1차,공24주,응용실시취합매련반응(polymerase chain reaction,PCR)정량법검측기치료전,치료12 h、1 d,2 d,3 d、1주、2주、4주、12주、24주적혈청을형간염병독(HBV)탈양핵당핵산(DNA),병응용회귀분석고계기병독동역학삼수.결과 공입선172례환자,년령16~65(31±10)세,남145례(84.3%),랍미부정용약후12 h즉출현명현적HBV DNA재량하강,평균하강0.45(범위:-1.85~3.86)lg(고패/m1),4례환자HBV DNA하강≥2 lg(고패/m1);2 d시진일보하강,여기선비교평균하강량1.20(범위:-1.21~4.41)lg(고패/ml);1주시계속하강,여기선비교,평균하강량2.01(범위:-0.17~5.79)lg(고패/ml).차후일직도24주,HBV DNA재량불단하강.24주시,평균하강량4.10(범위:-0.06~6.68)lg(고패/ml).유리병독반쇠기위2.57 d,수감염세포적반쇠기위63.0 d.결론 랍미부정치료HBeAg양성만성을형간염능쾌속강저HBV병독재량.
Objective To observe viral dynamic change in patients with HBeAg positive chronic hepatitis B by lamivudine treatment.Methods A multi-center clinical trial.Both outpatients and inpatients with HBeAg positive chronic hepatitis B have been administrated lamivudine 100 mg/d for 24 weeks.To detect the hepatitis B virus(HBV)deoxyribonucleic acid(DNA)levels of the baseline,12hours,1 day,2 days,3 days,1 week,2 weeks,4 weeks,12 weeks,24 weeks after lamivudine treatment by real time polymerase chain reaction(PCR).To estimate the parameters of viral dynamics through regression analysis.Results 172 patients were enrolled,145 male,30.8±9.7(16-65)years old Significant decrease of HBV DNA level occurred 12 hours after administration,the average decrease was 0.45 lg(copies/ml),maximum was 3.86 lg(copies/ml),4 patients decreased not less than 2 lg(copies/ml).On day 2 and 7,the average decrease was 1.20 lg(copies/ml)and 2.01 lg(copies/ml),maximum was 4.41 lg(copies/ml)and 5.79 lg(copies/ml),respectively.Then HBVDNA level continued decreasing until week 24.24-week administration of lamivudine cause 4.10 lg(copies/ml)decrease of HBV DNA averagely and 6.68 lg (copies/ml)mostly.Half life of free virion was 2.57 days.Half life of infected hepatocyte was 63.0 days.Conclusion Lamiviudine could rapidly decrease the HBVDNA level of patients with HBeAg positive chronic hepatitis B rapidly.